View Financial HealthThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsAgile Therapeutics 配当と自社株買い配当金 基準チェック /06Agile Therapeutics配当金を支払った記録がありません。主要情報n/a配当利回り-42.7%バイバック利回り総株主利回り-42.7%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Aug 27Exeltis USA, Inc. completed the acquisition of Agile Therapeutics, Inc. (OTCPK:AGRX) from Beryl Capital Management LLC and others.Exeltis USA, Inc. entered into a letter of intent to acquire Agile Therapeutics, Inc. (OTCPK:AGRX) from Beryl Capital Management LLC and others for $10.7 million on April 16, 2024. Exeltis USA, Inc. entered into a definitive merger agreement to acquire Agile Therapeutics, Inc. (OTCPK:AGRX) from Beryl Capital Management LLC and others for $10.7 million on June 25, 2024. Exeltis will acquire Agile for $1.52 per share in cash. In case of termination under certain circumstances, Agile would be required to pay Insud (parent of Exeltis) a termination fee of $1.26 million. Upon completion of the transaction, Agile will no longer be listed on any public market. Transaction is subject to approval by Agile’s stockholders. The Board of Directors of Agile has unanimously approved the transaction. The board of Insud Pharma, S.L. also approved the transaction. The transaction is expected to close in the third quarter of 2024. H.C. Wainwright & Co., LLC acted as financial advisor for Agile Therapeutics, Inc. Steven M. Cohen of Morgan, Lewis & Bockius LLP acted as legal advisor for Agile Therapeutics, Inc. Mitchell S. Nussbaum of Loeb & Loeb LLP and Xavier Ruiz of RC Law LLP acted as legal advisors to Insud Pharma, S.L. and Exeltis USA, Inc. H.C. Wainwright & Co., LLC acted as fairness opinion provider to Agile Therapeutics. Broadridge Financial Solutions, Inc. acted as transfer agent to Agile Therapeutics. The engagement letter between Agile and Wainwright provides for an advisory fee in an amount equal to $1.35 million to be paid to Wainwright at the closing of the Transactions. The engagement letter also provides for the payment to Wainwright of a fee in an amount equal to $0.35 million payable on the date on which the opinion was delivered that is not conditioned upon the results of Wainwright’s evaluation and analysis or upon the conclusions reached in the opinion. Alliance Advisors LLC acted as information agent to Agile Therapeutics, Inc. Exeltis USA, Inc. completed the acquisition of Agile Therapeutics, Inc. (OTCPK:AGRX) from Beryl Capital Management LLC and others on August 26, 2024. As of August 22, 2024, Agile Therapeutics shareholders approved the transaction. Loeb & Loeb LLP and RC Law LLP acted as legal advisors to Insud Pharma, S.L. and Exeltis USA, Inc.お知らせ • Jun 28Agile Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $15 million.Agile Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $15 million. Security Name: Common Stock Security Type: Common Stock Security Name: Series E-1 Warrants Security Type: Equity Warrant Security Name: Series E-2 Warrants Security Type: Equity Warrant Security Name: Series F Pre-funded Warrants Security Type: Equity Warrantお知らせ • Mar 28+ 1 more updateAgile Therapeutics, Inc.(OTCPK:AGRX) dropped from S&P TMI IndexAgile Therapeutics, Inc.(OTCPK:AGRX) dropped from S&P TMI Indexお知らせ • Mar 27Agile Therapeutics, Inc.(OTCPK:AGRX) dropped from NASDAQ Composite IndexAgile Therapeutics, Inc. will be removed from NASDAQ Composite Index.お知らせ • Mar 26Nasdaq to Suspend Common Stock of Agile Therapeutics Effective March 26On March 22, 2024, Agile Therapeutics, Inc. (the Company") received notice from The Nasdaq Stock Market LLC that the Nasdaq Hearings Panel has determined to delist the Company's common stock. Suspension of trading inthe Company's common stock will be effective at the open of trading on March 26, 2024. Following the delisting of its common stock from the Nasdaq Capital Market, the Company will continue to be a reporting company underthe Securities Exchange Act of 1934. The Company expects its common stock will commence trading on the OTC Markets Group platform at the open of trading on March 26, 2024 under the symbol AGRX." The Company has applied for trading on the OTC-QB market. The Company has a period of 15 days from the date of the notice letter to submit a written request for a review of the Nasdaq Hearings Panel's delisting determination by the Nasdaq Listing and Hearing Review Council (the Listing Council"). The Company does not plan to appeal the Nasdaq Hearings Panel's determination and expects that a Form 25-NSE will be filed with the Securities and Exchange Commission (SEC"), which would remove the Company's common stock from listing and registration on Nasdaq. As previously disclosed, on March 27, 2023, the Company received a letter from the Nasdaq Listing Qualifications Department (the Staff") indicating that it was not in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market set in Nasdaq Listing Rule 5550(b)(1) requiring companies listed on the Nasdaq Capital Market to maintain stockholder's equity of at least $2,500,000 (the Rule"). On June 2, 2023, based on the Staff's review of the materials submitted by the Company, the Staff granted the Company's request for an extension until September 25, 2023 to comply with the Rule. On September 27, 2023, the Company received a notice from the Staff advising the Company that the Staff had determined that the Company did not meet the terms of the extension and that unless the Company requested an appeal, the Staff would proceed with delisting. The Company submitted a hearing request to the Panel, which stayed the delisting, and the hearing was held on November 30, 2023. The Company was granted an additional period, or until March 25, 2024, to regain compliance with the Rule.お知らせ • Mar 22Agile Therapeutics, Inc. to Report Q4, 2023 Results on Mar 28, 2024Agile Therapeutics, Inc. announced that they will report Q4, 2023 results at 9:30 AM, US Eastern Standard Time on Mar 28, 2024お知らせ • Feb 16Agile Therapeutics, Inc. Provides Revenue Guidance for the Full Year Ended December 31, 2023Agile Therapeutics, Inc. provided revenue guidance for the Full Year ended December 31, 2023. For the year, the company expects net revenue to be in the range of $20 million to $21 million compared to $10.9 million for the full year 2022, representing an increase of 84% to 93%.お知らせ • Dec 12Agile Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.Agile Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $15 million. Security Name: Common Stock Security Type: Common Stock Security Name: Series E-1 Warrants Security Type: Equity Warrant Security Name: Series E-2 Warrants Security Type: Equity Warrant Security Name: Series F Pre-funded Warrants Security Type: Equity Warrantお知らせ • Oct 27Agile Therapeutics, Inc. to Report Q3, 2023 Results on Nov 09, 2023Agile Therapeutics, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 09, 2023お知らせ • Oct 05Agile Therapeutics Announces Update on Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital MarketAs previously disclosed on March 27, 2023, Agile Therapeutics, Inc. (the ‘Company’) received a letter from the Listing Qualifications Department (the ‘Staff’) of The Nasdaq Stock Market (‘Nasdaq’) indicating that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(b)(1) requiring companies listed on the Nasdaq Capital Market to maintain stockholder’s equity of at least $2,500,000 (the ‘Rule’). On June 2, 2023, based on the Staff’s review of the materials submitted by the Company, the Staff granted the Company’s request for an extension until September 25, 2023 to comply with the Rule. On September 27, 2023, the Company received a notice from the Staff advising the Company that the Staff had determined that the Company did not meet the terms of the extension and that unless the Company requests an appeal, the Staff would proceed with delisting. The Company intends to submit a hearing request to the Nasdaq Hearings Panel (the ‘Panel’), which request will stay any delisting action by the Staff at least until the hearing process concludes and any extension granted by the Panel expires. At the Panel hearing, the Company intends to present a plan to regain compliance with the Rule. In the interim, the Company’s common stock will continue to trade on the Nasdaq Capital Market at least pending the ultimate conclusion of the hearing process. Additionally, the Panel may review the Company’s plan and grant an additional 180 days from the date of the notice, until March 25, 2024, for the Company to regain compliance with the Rule. There can be no assurance that the Company’s plan will be accepted by the Panel or that, if it is, the Company will be able to regain compliance with the applicable Nasdaq listing requirements. If the Company’s common stock is delisted, it could be more difficult to buy or sell the Company’s common stock or to obtain accurate quotations, and the price of the Company’s common stock could suffer a material decline. Delisting could also impair the Company’s ability to raise capital. If trading in the Company’s common stock is suspended on the Nasdaq Capital Market or the Company’s common stock is delisted by Nasdaq, it could negatively impact the Company as it would likely reduce the liquidity and market price of the Company’s common stock, reduce the number of investors willing to hold or acquire the Company’s common stock, negatively impact the Company’s ability to access equity markets and obtain financing, and impair the Company’s ability to provide equity incentives.お知らせ • Jul 28Agile Therapeutics, Inc. to Report Q2, 2023 Results on Aug 09, 2023Agile Therapeutics, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 09, 2023お知らせ • Jul 01Agile Therapeutics, Inc. Provides Revenue Guidance for the Year 2023Agile Therapeutics, Inc. provides revenue guidance for the year 2023. For the year, the company expects $25-30 million in revenue largely due to Twirla.お知らせ • Jun 15Agile Therapeutics, Inc. (NasdaqCM:AGRX) announced an agreement to acquire vitaCare Prescription Services, Inc. from GoodRx Holdings, Inc. (NasdaqGS:GDRX).Agile Therapeutics, Inc. (NasdaqCM:AGRX) announced an agreement to acquire vitaCare Prescription Services, Inc. from GoodRx Holdings, Inc. (NasdaqGS:GDRX) on June 13, 2023.お知らせ • Jun 06Agile Therapeutics Receives an Additional 180-Day Period, or Until September 25, 2023 from Nasdaq, to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)On June 2, 2023, Agile Therapeutics, Inc. (the Company") received a letter (the Extension Notice") from the Listing Qualifications Department (the Staff") of The Nasdaq Stock Market (Nasdaq") notifying the Company thatit had been granted an additional 180-day period, or until September 25, 2023, to regain compliance with Nasdaq Listing Rule 5550(b)(1). As previously disclosed on March 27, 2023, the Company received a letter from theStaff indicating that it was not in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on the NasdaqCapital Market to maintain stockholders' equity of at least $2,500,000 (the Stockholders' Equity Requirement"). The Company's Annual Report on Form 10-K for the fourth quarter and year ended December 31, 2022, reportedstockholders' equity of $(5,545,000), which is below the Stockholders' Equity Requirement for continued listing on the Nasdaq Capital Market. The Company submitted a plan to regain compliance with the Stockholders' Equity Requirement under Nasdaq Listing Rule 5550(b)(1) on May 11, 2023. Pursuant to the Extension Notice, the Company must demonstrate compliance with Nasdaq Listing Rule 5550(b)(1) on or before September 25, 2023, by furnishing to the Securities and Exchange Commission (the SEC") and Nasdaq certain information and representations on a Current Report on Form 8-K, among other obligations. If, after submitting this information to the SEC and Nasdaq as described in the Extension Notice, the Company fails to evidence compliance with Nasdaq Listing Rule 5550(b)(1) upon filing its Form 10-Q for the quarter ended September 30, 2023, the Company may be subject to delisting from Nasdaq. In the event the Company fails to regain compliance, Nasdaq will issue the Company a delisting notice, at which time the Company would have the right to a hearing before an independent panel. The hearing request would halt any suspension or delisting action pending the conclusion of the hearing process and the expiration of any additional extension period granted by the panel following the hearing. The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq. If trading in the Company's common stock is suspended on Nasdaq or the Company's common stock is delisted by Nasdaq for any reason, it could negatively impact the Company as it would likely reduce the liquidity and market price of the Company's common stock; reduce the number of investors willing to hold or acquire the Company's common stock; negatively impact the Company's ability to access equity markets and obtain financing; and impair the Company's ability to provide equity incentives.お知らせ • May 26Agile Therapeutics, Inc. has completed a Follow-on Equity Offering.Agile Therapeutics, Inc. has completed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,896,286 Price\Range: $3.9551 Discount Per Security: $0.2769 Security Name: Series C-1 Warrants Security Type: Equity Warrant Securities Offered: 1,896,286 Security Name: Series C-2 Warrants Security Type: Equity Warrant Securities Offered: 1,896,286お知らせ • May 09Agile Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023Agile Therapeutics, Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 11, 2023お知らせ • Jan 10Agile Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023Agile Therapeutics, Inc. provided revenue guidance for the full year 2023. For the period, the company expects net revenue to be in the range of $25 million - $30 million.Seeking Alpha • Oct 10Agile appoints chief commercial officer from within ranks amid leadership revampAgile Therapeutics (NASDAQ:AGRX) said on Oct. 7 that it appointed Amy Welsh as chief commercial officer, effective Nov. 1, as part of a reorganization of its leadership team to to promote birth control patch Twirla (levonorgestrel and ethinyl estradiol). Welsh — who joined Agile in May 2020 as vice president, marketing — will lead the Twirla marketing team and will take responsibility for all the company's commercial functions. Meanwhile, James Tursi, resigned from the board, effective Oct. 7, to focus on his role as executive vice president, Global Research & Development of Endo Pharmaceuticals, the company said in an Oct. 7 press release. Agile noted that it does not plans to fill Tursi's seat. In addition, Agile said Geoffrey Gilmore was appointed to the newly created role of chief administrative officer. "In 2022, we have significantly reduced our operating expenses by redesigning how we work to gain efficiencies and implemented a plan we believe can drive Twirla growth through our Afaxys partnership, connected TV (CTV) campaign, and growing the telemedicine channel," said Agile Chairman and CEO Al Altomari.Seeking Alpha • Jul 11Agile gains as H.C. Wainwright sees 630% upside potentialAgile Therapeutics (NASDAQ:AGRX) rose sharply in the early trading on Monday after H.C. Wainwright doubled the price target on the women's healthcare company to a Street high of $5.00, citing its prospects following the recent Supreme Court ruling on abortion rights. In June, the U.S. Supreme Court ruled 6-3 to overturn the landmark 1973 decision in Roe v. Wade, prompting several retailers to temporarily impose purchase limits on emergency contraceptive pills. After the ruling, Agile (AGRX) should benefit with tailwinds for its lead product Twirla — the only low dose transdermal hormonal contraceptive, the analyst Oren Livnat argued, reaffirming the Buy rating on the stock. The new price target $5.00, up from $2.50 per share previously, implies a premium of ~630% to the last close. Evofem Biosciences (EVFM), a company selling an FDA-approved birth control method, has outperformed Agile (AGRX) after the Roe v. Wade ruling, as shown in this graph.Seeking Alpha • Jul 01Agile Therapeutics prices $24M upsized stock offeringAgile Therapeutics (NASDAQ:AGRX) announced Friday the pricing of its $24M upsized public offering that will comprise of 26.67M shares priced at $0.90 each. Each share of common stock in the offering is accompanied with Series A-1 warrant, exercisable to purchase second share at $0.90 each. The company said it intends to use the net proceeds for working capital, business development activities, and other general corporate purposes. Closing of the offering is expected on July 6, 2022. Earlier: Agile Therapeutics GAAP EPS of -$3.78 beats by $2.22, revenue of $1.76M beats by $0.54MSeeking Alpha • Apr 04Agile Therapeutics: Twirla's Lackluster Launch Forces Me To Change My StrategyAgile Therapeutics has finished its first full year as a commercial company and was able to establish an attractive growth curve for Twirla in several metrics. Slow uptake is forcing me to adjust my investment strategy to avoid locking up my capital while the company is burning through cash and the growth trajectory is uncertain. I review the company's Q4 and full-year 2021 earnings. The numbers were underwhelming but positive trends are budding. I have been waiting for a strong capitulation event. The recent sell-off could be that event. I discuss my new AGRX strategy.Seeking Alpha • Oct 19Agile Therapeutics: Bullish On Capitulation And Max PainAgile Therapeutics continues to trade under intense selling pressure. This selling amplified after the company announced a sizeable offering. My "house money" position has been mostly sitting on the sidelines waiting for a capitulation and "max pain" event. I discuss my strategy for taking advantage of these opportunities. Agile is launching Twirla right into strong COVID-19 headwinds. I don't expect the company to report outstanding earnings until the pandemic subsides. It looks as if the market is waiting for calmer waters and a clear heading before it supports AGRX. Bulls need to know when to stay the course or jump ship.Seeking Alpha • Jul 30Agile Therapeutics: Another Quarter Of Progress And Another Opportunity To BuyAgile Therapeutics recently reported their Q2 earnings with a beat on EPS and a miss on revenue. The company’s flagship product, Twirla, is already starting to display impressive growth trends. The market had a difficult time determining which direction it wants to take the share price, which has provided me an opportunity to add to my AGRX position. I will review the company's Q2 earnings and will highlight some key metrics for investors to follow as Twirla moves deeper into commercialization. I take a look at AGRX’s current valuation and will discuss how it influences the way I manage my position going forward.分析記事 • Feb 25How Many Agile Therapeutics, Inc. (NASDAQ:AGRX) Shares Did Insiders Buy, In The Last Year?It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...Is New 90 Day High Low • Feb 09New 90-day high: US$3.12The company is up 7.0% from its price of US$2.91 on 10 November 2020. The American market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 8.0% over the same period.分析記事 • Jan 04How Many Agile Therapeutics, Inc. (NASDAQ:AGRX) Shares Do Institutions Own?A look at the shareholders of Agile Therapeutics, Inc. ( NASDAQ:AGRX ) can tell us which group is most powerful...決済の安定と成長配当データの取得安定した配当: AGRXの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: AGRXの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Agile Therapeutics 配当利回り対市場AGRX 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (AGRX)n/a市場下位25% (US)1.3%市場トップ25% (US)4.1%業界平均 (Pharmaceuticals)1.9%アナリスト予想 (AGRX) (最長3年)n/a注目すべき配当: AGRXは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: AGRXは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: AGRXの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: AGRXが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/08/26 11:54終値2024/08/26 00:00収益2024/06/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Agile Therapeutics, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Kenneth TrbovichBrean Capital Historical (Janney Montgomery)Chiara RussoCantor Fitzgerald & Co.Corey DavisH.C. Wainwright & Co.4 その他のアナリストを表示
お知らせ • Aug 27Exeltis USA, Inc. completed the acquisition of Agile Therapeutics, Inc. (OTCPK:AGRX) from Beryl Capital Management LLC and others.Exeltis USA, Inc. entered into a letter of intent to acquire Agile Therapeutics, Inc. (OTCPK:AGRX) from Beryl Capital Management LLC and others for $10.7 million on April 16, 2024. Exeltis USA, Inc. entered into a definitive merger agreement to acquire Agile Therapeutics, Inc. (OTCPK:AGRX) from Beryl Capital Management LLC and others for $10.7 million on June 25, 2024. Exeltis will acquire Agile for $1.52 per share in cash. In case of termination under certain circumstances, Agile would be required to pay Insud (parent of Exeltis) a termination fee of $1.26 million. Upon completion of the transaction, Agile will no longer be listed on any public market. Transaction is subject to approval by Agile’s stockholders. The Board of Directors of Agile has unanimously approved the transaction. The board of Insud Pharma, S.L. also approved the transaction. The transaction is expected to close in the third quarter of 2024. H.C. Wainwright & Co., LLC acted as financial advisor for Agile Therapeutics, Inc. Steven M. Cohen of Morgan, Lewis & Bockius LLP acted as legal advisor for Agile Therapeutics, Inc. Mitchell S. Nussbaum of Loeb & Loeb LLP and Xavier Ruiz of RC Law LLP acted as legal advisors to Insud Pharma, S.L. and Exeltis USA, Inc. H.C. Wainwright & Co., LLC acted as fairness opinion provider to Agile Therapeutics. Broadridge Financial Solutions, Inc. acted as transfer agent to Agile Therapeutics. The engagement letter between Agile and Wainwright provides for an advisory fee in an amount equal to $1.35 million to be paid to Wainwright at the closing of the Transactions. The engagement letter also provides for the payment to Wainwright of a fee in an amount equal to $0.35 million payable on the date on which the opinion was delivered that is not conditioned upon the results of Wainwright’s evaluation and analysis or upon the conclusions reached in the opinion. Alliance Advisors LLC acted as information agent to Agile Therapeutics, Inc. Exeltis USA, Inc. completed the acquisition of Agile Therapeutics, Inc. (OTCPK:AGRX) from Beryl Capital Management LLC and others on August 26, 2024. As of August 22, 2024, Agile Therapeutics shareholders approved the transaction. Loeb & Loeb LLP and RC Law LLP acted as legal advisors to Insud Pharma, S.L. and Exeltis USA, Inc.
お知らせ • Jun 28Agile Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $15 million.Agile Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $15 million. Security Name: Common Stock Security Type: Common Stock Security Name: Series E-1 Warrants Security Type: Equity Warrant Security Name: Series E-2 Warrants Security Type: Equity Warrant Security Name: Series F Pre-funded Warrants Security Type: Equity Warrant
お知らせ • Mar 28+ 1 more updateAgile Therapeutics, Inc.(OTCPK:AGRX) dropped from S&P TMI IndexAgile Therapeutics, Inc.(OTCPK:AGRX) dropped from S&P TMI Index
お知らせ • Mar 27Agile Therapeutics, Inc.(OTCPK:AGRX) dropped from NASDAQ Composite IndexAgile Therapeutics, Inc. will be removed from NASDAQ Composite Index.
お知らせ • Mar 26Nasdaq to Suspend Common Stock of Agile Therapeutics Effective March 26On March 22, 2024, Agile Therapeutics, Inc. (the Company") received notice from The Nasdaq Stock Market LLC that the Nasdaq Hearings Panel has determined to delist the Company's common stock. Suspension of trading inthe Company's common stock will be effective at the open of trading on March 26, 2024. Following the delisting of its common stock from the Nasdaq Capital Market, the Company will continue to be a reporting company underthe Securities Exchange Act of 1934. The Company expects its common stock will commence trading on the OTC Markets Group platform at the open of trading on March 26, 2024 under the symbol AGRX." The Company has applied for trading on the OTC-QB market. The Company has a period of 15 days from the date of the notice letter to submit a written request for a review of the Nasdaq Hearings Panel's delisting determination by the Nasdaq Listing and Hearing Review Council (the Listing Council"). The Company does not plan to appeal the Nasdaq Hearings Panel's determination and expects that a Form 25-NSE will be filed with the Securities and Exchange Commission (SEC"), which would remove the Company's common stock from listing and registration on Nasdaq. As previously disclosed, on March 27, 2023, the Company received a letter from the Nasdaq Listing Qualifications Department (the Staff") indicating that it was not in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market set in Nasdaq Listing Rule 5550(b)(1) requiring companies listed on the Nasdaq Capital Market to maintain stockholder's equity of at least $2,500,000 (the Rule"). On June 2, 2023, based on the Staff's review of the materials submitted by the Company, the Staff granted the Company's request for an extension until September 25, 2023 to comply with the Rule. On September 27, 2023, the Company received a notice from the Staff advising the Company that the Staff had determined that the Company did not meet the terms of the extension and that unless the Company requested an appeal, the Staff would proceed with delisting. The Company submitted a hearing request to the Panel, which stayed the delisting, and the hearing was held on November 30, 2023. The Company was granted an additional period, or until March 25, 2024, to regain compliance with the Rule.
お知らせ • Mar 22Agile Therapeutics, Inc. to Report Q4, 2023 Results on Mar 28, 2024Agile Therapeutics, Inc. announced that they will report Q4, 2023 results at 9:30 AM, US Eastern Standard Time on Mar 28, 2024
お知らせ • Feb 16Agile Therapeutics, Inc. Provides Revenue Guidance for the Full Year Ended December 31, 2023Agile Therapeutics, Inc. provided revenue guidance for the Full Year ended December 31, 2023. For the year, the company expects net revenue to be in the range of $20 million to $21 million compared to $10.9 million for the full year 2022, representing an increase of 84% to 93%.
お知らせ • Dec 12Agile Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.Agile Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $15 million. Security Name: Common Stock Security Type: Common Stock Security Name: Series E-1 Warrants Security Type: Equity Warrant Security Name: Series E-2 Warrants Security Type: Equity Warrant Security Name: Series F Pre-funded Warrants Security Type: Equity Warrant
お知らせ • Oct 27Agile Therapeutics, Inc. to Report Q3, 2023 Results on Nov 09, 2023Agile Therapeutics, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 09, 2023
お知らせ • Oct 05Agile Therapeutics Announces Update on Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital MarketAs previously disclosed on March 27, 2023, Agile Therapeutics, Inc. (the ‘Company’) received a letter from the Listing Qualifications Department (the ‘Staff’) of The Nasdaq Stock Market (‘Nasdaq’) indicating that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(b)(1) requiring companies listed on the Nasdaq Capital Market to maintain stockholder’s equity of at least $2,500,000 (the ‘Rule’). On June 2, 2023, based on the Staff’s review of the materials submitted by the Company, the Staff granted the Company’s request for an extension until September 25, 2023 to comply with the Rule. On September 27, 2023, the Company received a notice from the Staff advising the Company that the Staff had determined that the Company did not meet the terms of the extension and that unless the Company requests an appeal, the Staff would proceed with delisting. The Company intends to submit a hearing request to the Nasdaq Hearings Panel (the ‘Panel’), which request will stay any delisting action by the Staff at least until the hearing process concludes and any extension granted by the Panel expires. At the Panel hearing, the Company intends to present a plan to regain compliance with the Rule. In the interim, the Company’s common stock will continue to trade on the Nasdaq Capital Market at least pending the ultimate conclusion of the hearing process. Additionally, the Panel may review the Company’s plan and grant an additional 180 days from the date of the notice, until March 25, 2024, for the Company to regain compliance with the Rule. There can be no assurance that the Company’s plan will be accepted by the Panel or that, if it is, the Company will be able to regain compliance with the applicable Nasdaq listing requirements. If the Company’s common stock is delisted, it could be more difficult to buy or sell the Company’s common stock or to obtain accurate quotations, and the price of the Company’s common stock could suffer a material decline. Delisting could also impair the Company’s ability to raise capital. If trading in the Company’s common stock is suspended on the Nasdaq Capital Market or the Company’s common stock is delisted by Nasdaq, it could negatively impact the Company as it would likely reduce the liquidity and market price of the Company’s common stock, reduce the number of investors willing to hold or acquire the Company’s common stock, negatively impact the Company’s ability to access equity markets and obtain financing, and impair the Company’s ability to provide equity incentives.
お知らせ • Jul 28Agile Therapeutics, Inc. to Report Q2, 2023 Results on Aug 09, 2023Agile Therapeutics, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 09, 2023
お知らせ • Jul 01Agile Therapeutics, Inc. Provides Revenue Guidance for the Year 2023Agile Therapeutics, Inc. provides revenue guidance for the year 2023. For the year, the company expects $25-30 million in revenue largely due to Twirla.
お知らせ • Jun 15Agile Therapeutics, Inc. (NasdaqCM:AGRX) announced an agreement to acquire vitaCare Prescription Services, Inc. from GoodRx Holdings, Inc. (NasdaqGS:GDRX).Agile Therapeutics, Inc. (NasdaqCM:AGRX) announced an agreement to acquire vitaCare Prescription Services, Inc. from GoodRx Holdings, Inc. (NasdaqGS:GDRX) on June 13, 2023.
お知らせ • Jun 06Agile Therapeutics Receives an Additional 180-Day Period, or Until September 25, 2023 from Nasdaq, to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)On June 2, 2023, Agile Therapeutics, Inc. (the Company") received a letter (the Extension Notice") from the Listing Qualifications Department (the Staff") of The Nasdaq Stock Market (Nasdaq") notifying the Company thatit had been granted an additional 180-day period, or until September 25, 2023, to regain compliance with Nasdaq Listing Rule 5550(b)(1). As previously disclosed on March 27, 2023, the Company received a letter from theStaff indicating that it was not in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on the NasdaqCapital Market to maintain stockholders' equity of at least $2,500,000 (the Stockholders' Equity Requirement"). The Company's Annual Report on Form 10-K for the fourth quarter and year ended December 31, 2022, reportedstockholders' equity of $(5,545,000), which is below the Stockholders' Equity Requirement for continued listing on the Nasdaq Capital Market. The Company submitted a plan to regain compliance with the Stockholders' Equity Requirement under Nasdaq Listing Rule 5550(b)(1) on May 11, 2023. Pursuant to the Extension Notice, the Company must demonstrate compliance with Nasdaq Listing Rule 5550(b)(1) on or before September 25, 2023, by furnishing to the Securities and Exchange Commission (the SEC") and Nasdaq certain information and representations on a Current Report on Form 8-K, among other obligations. If, after submitting this information to the SEC and Nasdaq as described in the Extension Notice, the Company fails to evidence compliance with Nasdaq Listing Rule 5550(b)(1) upon filing its Form 10-Q for the quarter ended September 30, 2023, the Company may be subject to delisting from Nasdaq. In the event the Company fails to regain compliance, Nasdaq will issue the Company a delisting notice, at which time the Company would have the right to a hearing before an independent panel. The hearing request would halt any suspension or delisting action pending the conclusion of the hearing process and the expiration of any additional extension period granted by the panel following the hearing. The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq. If trading in the Company's common stock is suspended on Nasdaq or the Company's common stock is delisted by Nasdaq for any reason, it could negatively impact the Company as it would likely reduce the liquidity and market price of the Company's common stock; reduce the number of investors willing to hold or acquire the Company's common stock; negatively impact the Company's ability to access equity markets and obtain financing; and impair the Company's ability to provide equity incentives.
お知らせ • May 26Agile Therapeutics, Inc. has completed a Follow-on Equity Offering.Agile Therapeutics, Inc. has completed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,896,286 Price\Range: $3.9551 Discount Per Security: $0.2769 Security Name: Series C-1 Warrants Security Type: Equity Warrant Securities Offered: 1,896,286 Security Name: Series C-2 Warrants Security Type: Equity Warrant Securities Offered: 1,896,286
お知らせ • May 09Agile Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023Agile Therapeutics, Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 11, 2023
お知らせ • Jan 10Agile Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023Agile Therapeutics, Inc. provided revenue guidance for the full year 2023. For the period, the company expects net revenue to be in the range of $25 million - $30 million.
Seeking Alpha • Oct 10Agile appoints chief commercial officer from within ranks amid leadership revampAgile Therapeutics (NASDAQ:AGRX) said on Oct. 7 that it appointed Amy Welsh as chief commercial officer, effective Nov. 1, as part of a reorganization of its leadership team to to promote birth control patch Twirla (levonorgestrel and ethinyl estradiol). Welsh — who joined Agile in May 2020 as vice president, marketing — will lead the Twirla marketing team and will take responsibility for all the company's commercial functions. Meanwhile, James Tursi, resigned from the board, effective Oct. 7, to focus on his role as executive vice president, Global Research & Development of Endo Pharmaceuticals, the company said in an Oct. 7 press release. Agile noted that it does not plans to fill Tursi's seat. In addition, Agile said Geoffrey Gilmore was appointed to the newly created role of chief administrative officer. "In 2022, we have significantly reduced our operating expenses by redesigning how we work to gain efficiencies and implemented a plan we believe can drive Twirla growth through our Afaxys partnership, connected TV (CTV) campaign, and growing the telemedicine channel," said Agile Chairman and CEO Al Altomari.
Seeking Alpha • Jul 11Agile gains as H.C. Wainwright sees 630% upside potentialAgile Therapeutics (NASDAQ:AGRX) rose sharply in the early trading on Monday after H.C. Wainwright doubled the price target on the women's healthcare company to a Street high of $5.00, citing its prospects following the recent Supreme Court ruling on abortion rights. In June, the U.S. Supreme Court ruled 6-3 to overturn the landmark 1973 decision in Roe v. Wade, prompting several retailers to temporarily impose purchase limits on emergency contraceptive pills. After the ruling, Agile (AGRX) should benefit with tailwinds for its lead product Twirla — the only low dose transdermal hormonal contraceptive, the analyst Oren Livnat argued, reaffirming the Buy rating on the stock. The new price target $5.00, up from $2.50 per share previously, implies a premium of ~630% to the last close. Evofem Biosciences (EVFM), a company selling an FDA-approved birth control method, has outperformed Agile (AGRX) after the Roe v. Wade ruling, as shown in this graph.
Seeking Alpha • Jul 01Agile Therapeutics prices $24M upsized stock offeringAgile Therapeutics (NASDAQ:AGRX) announced Friday the pricing of its $24M upsized public offering that will comprise of 26.67M shares priced at $0.90 each. Each share of common stock in the offering is accompanied with Series A-1 warrant, exercisable to purchase second share at $0.90 each. The company said it intends to use the net proceeds for working capital, business development activities, and other general corporate purposes. Closing of the offering is expected on July 6, 2022. Earlier: Agile Therapeutics GAAP EPS of -$3.78 beats by $2.22, revenue of $1.76M beats by $0.54M
Seeking Alpha • Apr 04Agile Therapeutics: Twirla's Lackluster Launch Forces Me To Change My StrategyAgile Therapeutics has finished its first full year as a commercial company and was able to establish an attractive growth curve for Twirla in several metrics. Slow uptake is forcing me to adjust my investment strategy to avoid locking up my capital while the company is burning through cash and the growth trajectory is uncertain. I review the company's Q4 and full-year 2021 earnings. The numbers were underwhelming but positive trends are budding. I have been waiting for a strong capitulation event. The recent sell-off could be that event. I discuss my new AGRX strategy.
Seeking Alpha • Oct 19Agile Therapeutics: Bullish On Capitulation And Max PainAgile Therapeutics continues to trade under intense selling pressure. This selling amplified after the company announced a sizeable offering. My "house money" position has been mostly sitting on the sidelines waiting for a capitulation and "max pain" event. I discuss my strategy for taking advantage of these opportunities. Agile is launching Twirla right into strong COVID-19 headwinds. I don't expect the company to report outstanding earnings until the pandemic subsides. It looks as if the market is waiting for calmer waters and a clear heading before it supports AGRX. Bulls need to know when to stay the course or jump ship.
Seeking Alpha • Jul 30Agile Therapeutics: Another Quarter Of Progress And Another Opportunity To BuyAgile Therapeutics recently reported their Q2 earnings with a beat on EPS and a miss on revenue. The company’s flagship product, Twirla, is already starting to display impressive growth trends. The market had a difficult time determining which direction it wants to take the share price, which has provided me an opportunity to add to my AGRX position. I will review the company's Q2 earnings and will highlight some key metrics for investors to follow as Twirla moves deeper into commercialization. I take a look at AGRX’s current valuation and will discuss how it influences the way I manage my position going forward.
分析記事 • Feb 25How Many Agile Therapeutics, Inc. (NASDAQ:AGRX) Shares Did Insiders Buy, In The Last Year?It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
Is New 90 Day High Low • Feb 09New 90-day high: US$3.12The company is up 7.0% from its price of US$2.91 on 10 November 2020. The American market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 8.0% over the same period.
分析記事 • Jan 04How Many Agile Therapeutics, Inc. (NASDAQ:AGRX) Shares Do Institutions Own?A look at the shareholders of Agile Therapeutics, Inc. ( NASDAQ:AGRX ) can tell us which group is most powerful...